Drugs in Dev. Dermatology
Phase IV
Lead Product(s) : Deucravacitinib
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bristol Myers Shows Sotyktu Efficacy in Scalp Psoriasis And Real-World Data
Details : Sotyktu (deucravacitinib) is an oral, selective, allosteric TYK2 inhibitor. It inhibits the signaling of IL-23/12 and Type 1 IFN, cytokines involved in the pathogenesis of immune-mediated diseases.
Product Name : BMS-986165
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2024
Lead Product(s) : Deucravacitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vtama (tapinarof) is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant and steroid-free, topical cream, for the treatment of plaque psoriasis in the head and neck region.
Product Name : Vtama
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prabotulinumtoxin A
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Daewoong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The two Phase II studies, conducted to support the registration and regulatory approval of Jeuveau® in the United States, Canada and Europe, demonstrate that prolonged use of Jeuveau is safe and effective with repeat treatments.
Product Name : Jeuveau
Product Type : Protein
Upfront Cash : Inapplicable
December 05, 2021
Lead Product(s) : Prabotulinumtoxin A
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Daewoong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prabotulinumtoxin A
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau® in Patients with Skin of Color
Details : The article focuses on pooled data from 492 Jeuveau®-treated patients who participated in two US multicenter, randomized, double-blind, placebo-controlled, single-dose phase III clinical studies.
Product Name : Jeuveau
Product Type : Protein
Upfront Cash : Inapplicable
June 24, 2021
Lead Product(s) : Prabotulinumtoxin A
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Top-line results showed that 95% of patients treated with Dysport were revealed from severe glabellar lines with two treatments per year, and for 97% the result of the treatment seemed natural.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 05, 2020
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
